A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

Giorgio V. Scagliotti, Paul Germonpré, Leon Bosquée, Johan Vansteenkiste, R. Gervais, David Planchard, Martin Reck, Filippo De Marinis, Jin Soo Lee, Keunchil Park, Bonne Biesma, Steven Gans, R. Ramlau, Aleusandra Szczesna, A. Makhson, G. Manikhas, Bruno Morgan, Y. Zhu, Kai C. Chan, Joachim von Pawel

Research output: Contribution to journalArticlepeer-review

Abstract

Background: This is a phase II randomized study to evaluate the efficacy and safety of bortezomib and pemetrexed alone or in combination, in patients with previously treated advanced non-small-cell lung cancer (NSCLC). The primary end point was assessment of response rate. Methods: A total of 155 patients were randomized (1:1:1) to pemetrexed (500mg/m2) on day 1 plus bortezomib (1.6mg/m2) on days 1 and 8 (Arm A) or pemetrexed (500mg/m2) on day 1 (Arm B) or bortezomib (1.6mg/m2) on days 1 and 8 (Arm C) of a 21 day cycle. Response rate was assessed by investigators using Response Evaluation Criteria In Solid Tumors (RECIST) criteria and toxicity assessed by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading system. Results: Response rate was 7% in Arm A, 4% in Arm B, and 0% in Arm C; disease control rates were 73%, 62%, and 43%, respectively. Median overall survival was 8.6 months in Arm A, 12.7 months in Arm B, and 7.8 months in Arm C; time to progression was 4.0 months, 2.9 months, and 1.4 months, respectively. Most common reported adverse events ≥grade 3 were neutropenia (19%), thrombocytopenia (15%), and dyspnea (13%) in Arm A, neutropenia (10%) in Arm B, and dyspnea (13%) and fatigue (10%) in Arm C. Conclusion: In previously treated NSCLC the addition of bortezomib to pemetrexed was well tolerated but offered no statistically significant response or survival advantage versus pemetrexed alone, while bortezomib alone showed no clinically significant activity.

Original languageEnglish
Pages (from-to)420-426
Number of pages7
JournalLung Cancer
Volume68
Issue number3
DOIs
Publication statusPublished - Jun 2010

Keywords

  • Bortezomib
  • Non-small-cell lung cancer
  • Pemetrexed

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Medicine(all)

Fingerprint Dive into the research topics of 'A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this